Drug intelligence / Profile preview

FKC211

Development stage: Unknown
Lead developer: Fosun Pharma USA
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FKC211 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting folate receptor alpha (FOLR1). Developed by Fosun Pharma USA, it is designed for the treatment of epithelial ovarian cancer (EOC), a malignancy where FOLR1 is often highly expressed. The therapy involves the ex vivo genetic modification of a patient's own T cells to express a CAR specific to FOLR1, which, upon re-infusion, enables the T cells to recognize and eliminate FOLR1-positive tumor cells. FKC211 is currently in Phase 1 clinical development.

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on FKC211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FKC211.